Elicio Therapeutics, Inc. Stock Price, News & Analysis

Elicio Therapeutics (NASDAQ: ELTX) has secured $10 million in financing through a senior secured promissory note with GKCC, LLC. The note bears a 12.5% interest rate, matures in June 2028, and includes warrant issuance for 103,225 shares at $7.75 per share. This funding extends Elicio's operations into Q1 2026, beyond their crucial AMPLIFY-7P Phase 2 interim analysis for ELI-002 expected in Q3 2025. ELI-002 is their lead program targeting mKRAS mutations in pancreatic and colorectal cancers. Previous Phase 1 data showed promising results with 16.3-month median recurrence-free survival and 28.9-month median overall survival. The company plans to explore combination therapies and expand into other cancer indications.

Elicio Therapeutics (NASDAQ: ELTX) reported its Q1 2025 financial results and provided corporate updates. The company is advancing toward a crucial Phase 2 AMPLIFY-7P interim analysis expected in Q3 2025, focusing on disease-free survival in pancreatic cancer treatment. Key financial highlights include: R&D expenses of $7.8M (up from $7.6M in Q1 2024), G&A expenses of $3.0M (up from $2.7M), and a net loss of $11.2M ($0.87 per share). The company's cash position of $18.4M is expected to support operations into Q4 2025.

Notable developments include FDA alignment on key Phase 3 study design elements for ELI-002, appointment of Preetam Shah as Chief Strategy and Financial Officer, and a $10M registered direct offering. ELI-002 represents a potential breakthrough in treating mKRAS-driven tumors, particularly for pancreatic cancer patients with a 13% 5-year survival rate.

Elicio Therapeutics (Nasdaq: ELTX) has announced inducement awards for its newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two other new employees. The grants were approved under the Elicio 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Dr. Shah received 191,624 stock options, while the two additional employees were granted a total of 21,000 stock options. All options are priced at $4.98 per share, matching Elicio's closing price on April 15, 2025. The options vest over four years, with 25% vesting on the first employment anniversary and the remainder vesting monthly thereafter, contingent on continued employment.

Elicio Therapeutics (NASDAQ: ELTX) reported its 2024 financial results and provided corporate updates. The company completed enrollment of 144 patients in its Phase 2 AMPLIFY-7P randomized study, with disease-free survival interim analysis expected in Q3 2025. Key financial results include:

- R&D expenses increased to $33.7M (vs $23.8M in 2023)
- G&A expenses decreased to $11.3M (vs $11.9M in 2023)
- Net loss widened to $51.9M (vs $35.2M in 2023)
- Cash position of $17.6M as of December 31, 2024

The company strengthened its position with a $10M registered direct offering in January 2025, extending operations into Q4 2025. Elicio aligned with FDA on key elements of planned ELI-002 Phase 3 study design and presented encouraging Phase 1a data showing 16.3-month median recurrence-free survival and 28.9-month median overall survival.

Elicio Therapeutics (Nasdaq: ELTX) has appointed Preetam Shah, Ph.D., MBA as Chief Strategy and Financial Officer. Dr. Shah brings extensive leadership experience from previous roles as CFO and CBO at multiple public biotech companies.

The appointment comes at a important time as Elicio approaches the disease-free survival event-driven interim analysis for its Phase 2 AMPLIFY-7P study. The company is developing ELI-002 and its Amphiphile platform for cancer immunotherapy treatments.

Dr. Shah's prior experience includes serving as CFO/CBO at Cidara Therapeutics, where he managed corporate financings and business development. He also held executive positions at Brainstorm Cell Therapeutics and investment banking roles at Barclays Capital and Canaccord Genuity. He holds a Ph.D. in microbiology and an MBA from Wharton.

Elicio Therapeutics (Nasdaq: ELTX) has announced a $10.0 million registered direct offering priced at-the-market under Nasdaq rules. The offering includes 1,261,830 shares of common stock and accompanying warrants to purchase an equal number of shares at a purchase price of $7.925 per share and warrant.

The warrants will have an exercise price of $7.80 per share, will be immediately exercisable upon issuance, and will expire after five years. The offering is expected to close around January 30, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent.

The company plans to use the net proceeds for working capital and general corporate purposes. The offering is being made through an effective shelf registration statement filed with the SEC.

Elicio Therapeutics (ELTX) has received supportive FDA feedback regarding the registrational strategy for its cancer immunotherapy candidate ELI-002. The FDA alignment covers key elements of the potential Phase 3 study design, including dose, schedule, patient population (KRAS-mutated pancreatic adenocarcinoma), and primary endpoint analysis of disease-free survival.

The company's Phase 2 randomized study of ELI-002 is fully enrolled, with a formal interim analysis of disease-free survival expected in H1 2025. Positive results could support rapid advancement into Phase 3 development. The therapy has shown encouraging clinical results with a favorable safety profile and strong correlation between T cell response, tumor biomarker reductions, and reduced risk of recurrence or death.

ELI-002 is being developed as an off-the-shelf monotherapy for patients who completed chemotherapy but remain at elevated risk of disease recurrence.

Elicio Therapeutics (ELTX) presented updated Phase 1 AMPLIFY-201 trial results for ELI-002, their cancer vaccine targeting KRAS-mutant tumors. With 19.7 months median follow-up, the study showed 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) in the full study population of 25 patients with colorectal or pancreatic cancer.

The trial demonstrated strong correlation between T cell response and survival outcomes. Patients with above-median T cell responses hadn't reached mRFS, while those below median achieved 4.0-month mRFS. The vaccine showed favorable safety profile with no Grade 3/4 adverse events. ELI-002's seven-peptide formulation is currently in Phase 2 trials, with interim analysis expected in H1 2025.

Elicio Therapeutics has completed enrollment for its Phase 2 AMPLIFY-7P study, evaluating ELI-002 7P in patients with mKRAS-driven pancreatic ductal adenocarcinoma. The randomized trial enrolled 135 patients, exceeding enrollment speed expectations. Patients were randomized 2:1 to receive ELI-002 7P versus standard care observation, with crossover allowed upon disease progression. The study's primary endpoint is disease-free survival (DFS), with a formal interim analysis expected in H1 2025. The trial follows successful Phase 1a results that showed favorable safety profiles and robust T-cell responses.